JPMorgan Chase & Co. Has $2.20 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

JPMorgan Chase & Co. lifted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 2.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,007,519 shares of the company’s stock after purchasing an additional 20,236 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.42% of Ventyx Biosciences worth $2,196,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares in the last quarter. State Street Corp grew its holdings in shares of Ventyx Biosciences by 0.8% during the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after purchasing an additional 9,783 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in shares of Ventyx Biosciences during the 3rd quarter worth approximately $26,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Ventyx Biosciences by 3.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company’s stock valued at $1,058,000 after buying an additional 17,898 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Wall Street Analysts Forecast Growth

VTYX has been the topic of several recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Insiders Place Their Bets

In other Ventyx Biosciences news, insider John Nuss sold 13,161 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total value of $29,743.86. Following the transaction, the insider now owns 485,701 shares of the company’s stock, valued at approximately $1,097,684.26. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sheila Gujrathi bought 130,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were purchased at an average price of $2.31 per share, with a total value of $300,300.00. Following the transaction, the director now owns 130,000 shares of the company’s stock, valued at $300,300. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 630,000 shares of company stock valued at $1,262,415. 18.18% of the stock is currently owned by corporate insiders.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $2.08 on Wednesday. The firm has a market cap of $147.08 million, a P/E ratio of -0.88 and a beta of 0.55. The business’s fifty day moving average is $2.27 and its two-hundred day moving average is $2.27. Ventyx Biosciences, Inc. has a 52 week low of $1.67 and a 52 week high of $11.48.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.